Bodyport

Predicting and preventing heart disease.

About

Founded

2015

Headquarters

San Francisco, California

Industry

Healthcare, Hardware

Company Description

We are a biomarker-guided digital therapeutics company that aims to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. With one simple step, every person can access comprehensive health insights in their own home. Now patients and their care teams can better predict, understand, and intervene in worsening health to prevent hospitalizations and improve quality of life.

Quick Links

WebsiteJobs

Funding

Total Raised

$15.8 million

Valuation

Undisclosed

Significant Investors

Hardware Club, Boehringer Ingelheim Venture Fund, Playground Global, Initialized Capital, Y Combinator

Company Traction

  • In August 2022, Bodyport received FDA clearance for its cardiac scale.
  • As of August 2022, 10 hospitals and healthcare systems have already participated in Bodyport’s clinical trials.

Leadership Team

  • John Lipman: CEO at Bodyport. Former President, North America at Quanta Dialysis Technologies.
  • Corey Centen: Co-Founder, President, and CTO of Bodyport. Former Co-Founder & CEO of Atreo Medical.
  • Sarah Smith: Co-Founder & CPO of Bodyport. Former Co-Founder & COO of Atreo Medical.
  • Kivanc Ozonat: Head of Data Science at Bodyport. Former Head of Data Science at Spry Health.